RetroSense Therapuetics Logowhite spacerGo to about RetroSenseGo to Investors and Partners pageGo to Product DevelopmentGo to Therapeutics AreasGo to Frequently Asked QuestionsGo to Contact Page
left image bandRight Image band
photoRetroSense Therapeutics develops game-changing gene therapy solutions to restore partial sight for certain eye diseases.
Investors | Partners

 

 

 

 

 








 

 

 

 

 

RetroSense at a Glance

Company RetroSense Therapeutics, LLC

Industry Biopharmaceutical

Capital
Structure
Funded by Foundation Fighting Blindness / National Neurovision Research Institute, private investors, Michigan Economic Development Corporation

Therapeutic Category

Retinal degenerative conditions
Significant Unmet Medical Need In spite of decades of research and development efforts, there are currently no FDA approved therapies for the treatment of either retinitis pigmentosa or dry age-related macular degeneration. There are currently 100k people with retinitis pigmentosa and 1 million with advanced dry age-related macular degeneration in the US.

Business Development

Actively seeking partnerships and collaborations
Location
Ann Arbor, Michigan

Font Size